We ended the quarter with cash, cash equivalents and short term investments of $108,400,000 compared to $77,300,000 as of the 2024. Turning to our financial outlook for 2025, we're raising our total revenue guidance to approximately $270,000,000 to $280,000,000 an increase from our prior range of $200,000,000 to $210,000,000 This includes updated net product sales expectations of approximately $210,000,000 to $220,000,000 an increase from the prior range of $185,000,000 to $192,000,000 and contract revenues from collaborations of approximately $60,000,000 an increase from the prior range of $15,000,000 to $18,000,000 The updated total revenues and contract revenues from collaborations expectations are inclusive of the $40,000,000 in non cash contract revenue related to Rigel's agreement with Lilly. In addition, we continue to anticipate that we will report positive net income for the full year 2025, while funding existing and new clinical development programs. To wrap up my section, we look forward to continued financial discipline for the remainder of 2025 and beyond. With that, I'd like to turn the call back over to Raul.